Orexo US Blog Contact EN About Us Key Therapeutic Areas Pharmaceuticals Digital Therapies Sustainability Investors Media What we do Pharmaceuticals Commercializing and developing pharmaceuticals addressing large unmet needs LEARN MORE Digital Therapeutics Product portfolio of scientifically proven digital therapies LEARN MORE Mental illness & substance use disorders Focusing on areas of great human suffering with wider societal implications LEARN MORE MODIA™ - our digital therapy for opioid dependence to be used along with pharmaceuticals 6 months treatment grounded in cognitive behavioral therapy techniques available 24/7 ongoing clinical trial incl. up to 400 patients EXPLORE MORE Key News NOVEMBER 26, 2021 Orexo provides information about its new proprietary drug delivery platform – amorphOX™ GO TO PR NOVEMBER 16, 2021 Positive results from pivotal trial for OX124 GO TO PR NOVEMBER 3, 2021 Q3 Interim Report - Steady progression on our journey to build a broader and stronger Orexo READ THE PR Orexo Social @OrexoABpubl 26 November 2021 amorphOX™, is an inventive powder-based technology, that is very rapidly dissolving, stable & works with different… https://t.co/uuH4sJEwfT @OrexoABpubl 26 November 2021 Today we are proud to inform about the amorphOX™ platform, our new proprietary drug delivery technology, which will… https://t.co/V0s2CTLGcQ @OrexoABpubl 18 November 2021 The number of overdose deaths has surpassed 100,000 annually for the first time in history. #Fentanyl #opioidcrisis… https://t.co/KFnCNdTi3J Our history Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995. FIND OUT MORE News Flow Regulatory Press Releases Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124 16 November 2021 · Press Release · Regulatory Orexo Q3 2021 Interim Report 3 November 2021 · Report · Regulatory Orexo Q2 2021 Interim Report 15 July 2021 · Report · Regulatory Orexo Q1 2021 Interim Report 29 April 2021 · Report · Regulatory Press Releases & News Orexo provides information about its new proprietary drug delivery platform – amorphOX™ 26 November 2021 · Press Release Orexo´s Nomination Committee for the Annual General Meeting 2022 1 November 2021 · Press Release Invitation to presentation of Orexo´s Q3 Interim Report, on November 3 at 1 pm CET 22 October 2021 · Invitation MODIA™ paper published in the Journal of Medical Internet Research Mental Health 18 October 2021 · Press Release Financial Snapshot Group net revenues 580 MSEK LTM1 Group EBITDA -112 MSEK LTM1 US Pharma segment EBIT 301 MSEK LTM1 Cash position 588 MSEK Q3 2021 1 Last Twelve Months, Q420-Q321, for more information about financial development Link Thanks and welcome back! ©2021 Orexo AB (publ.) – All rights reserved Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy